ReviewDrugs2023
Talquetamab: First Approval.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Infection risk associated with talquetamab in relapsed/refractory multiple myeloma: a systematic review with meta-analysis of talquetamab monotherapy and descriptive analysis of combination therapy.Frontiers in immunology · 2026Pooled it
- Review
- Advances in Oncohematology Immunotherapy: Monoclonal Antibodies and CAR T-Cell Therapies.Cells · 2026Review
- Bispecific antibodies for cancer therapy: evolution of structural formats and co-targeting strategies from wet-lab to AI-driven in silico modeling.Cancer letters · 2026Review
- Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.Blood advances · 2026Article
- Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026Review
- Discovery of co-stimulatory anti-CD28 VHHs for developing cancer immune therapeutic anti-tumor/CD3/CD28 trispecific T cell engager.Frontiers in immunology · 2026Article
- Pharmacological Insights on USFDA-approved Novel Drug Therapies in the Year 2023.Current drug discovery technologies · 2026Review
- Article
- Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.Blood cancer journal · 2025Article
- Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.British journal of haematology · 2025Review
- Review
- Bispecific antibodies: unleashing a new era in oncology treatment.Molecular cancer · 2025Review
- Pharmacological aspects of FDA-approved novel drug therapies against cancer in 2023: a comprehensive review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Polypharmacology: new drugs in 2023-2024.Pharmacological reports : PR · 2025Review
- Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.Innovation (Cambridge (Mass.)) · 2025Review
- Characteristics of second primary malignancies following bispecific antibodies therapy.Journal for immunotherapy of cancer · 2025Article
- The Use of Biologics for Targeting GPCRs in Metastatic Cancers.Biotech (Basel (Switzerland)) · 2025Review
- Leveraging T cells for cancer immunotherapy.Immunity & inflammation · 2025Review
- The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Talquetamab (talquetamab-tgvs; TALVEY
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.